Press Releases and Events

PRESS RELEASES

Press Release | May 10, 2024

Crinetics Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | May 9, 2024

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

READ MORE
Press Release | May 8, 2024

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

READ MORE
Press Release | April 11, 2024

Crinetics Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | March 19, 2024

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

READ MORE
Press Release | March 12, 2024

Crinetics Announces Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

READ MORE
Press Release | March 11, 2024

Crinetics Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | February 28, 2024

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

READ MORE
Press Release | February 28, 2024

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement

READ MORE
Press Release | February 12, 2024

Crinetics Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
8 / 24